Life Flight Network Announces Timeline for Expansion into Hawai'i, Investing $27M in New Air Medical Operations
AURORA, Ore., June 12, 2025 /PRNewswire/ -- Life Flight Network, the nation's largest not-for-profit air ambulance provider, is proud to announce the launch of its operations on the island of Hawai'i, beginning this fall. Life Flight Network will invest $27 million into its Hawai'i operations, building on the previously announced $15 million investment from the Daniel R. Sayre Memorial Foundation through the acquisition of a new Airbus H145 helicopter. This funding will cover aircraft acquisition, medical equipment, and facilities for three bases on the Big Island, expanding critical care access for residents and visitors.
"Our team has spent the past several months listening to and learning from community leaders, hospital partners, and public officials across Hawai'i," said Ben Clayton, CEO of Life Flight Network. "We've heard firsthand about the challenges patients face in accessing timely, high-quality emergency medical transportation. Our goal is to increase access, improve outcomes, and save lives. We're honored to serve the people of Hawai'i and proud to partner with the Daniel R. Sayre Memorial Foundation in supporting the health and safety of these communities."
Life Flight Network has received a warm welcome from the Big Island, including support from Mayor Kimo Alameda. "Ensuring the safety and well-being of our Hawai'i Island community is my top priority, and I'm excited to welcome Life Flight Network to the Big Island," said the mayor. "Their decision to open multiple bases here strengthens our emergency response capabilities and brings critical care closer to our rural and remote areas. This partnership is an important step in protecting the lives of both residents and visitors."
This support is echoed by local healthcare leaders. Hawai'i Health Systems' Hawai'i West Region CEO, Clayton McGhan, added, "We welcome Life Flight Network's expansion to Hawai'i Island, where access to timely emergency care can mean the difference between life and death. Enhancing air medical transport capacity is vital for rural communities like ours, and this investment represents an important step in strengthening the island's overall emergency response system."
In partnership with Queen's North Hawai'i Community Hospital and Kona Community Hospital, Life Flight Network will initially station an Airbus EC135P2+ helicopter at each facility. These will transition to Airbus H145 helicopters by mid-2026. Additionally, a Pilatus PC-12NG fixed-wing aircraft will be based at Hilo International Airport. The ramp-up to full operations will begin this fall.
In addition, and through a unique partnership with the Daniel R. Sayre Memorial Foundation, Life Flight Network will operate a new Airbus H145D3 helicopter on behalf of the foundation. The Daniel R. Sayre Memorial Foundation acquired the helicopter through the generosity of many donors to improve access to air ambulance services and chose Life Flight Network to operationalize the asset.
"This partnership is rooted in a shared mission to save lives," said Dominic Pomponio, Chief Business Officer at Life Flight Network. "Our Hawai'i operations represent a significant investment in the people of Hawai'i—not only through aircraft and equipment, but also by hiring highly trained personnel who will serve this community 24/7."
Life Flight Network's bases in Hilo, Kona, and Waimea will support emergency transports between the hospitals and from the Big Island to O'ahu. "We are pleased that Life Flight Network will be offering our residents and visitors another option for critical air medical transport," said Stephany Nihipali Vaioleti, President at Queens North Hawai'i Community Hospital. "We all know the importance of our most critically ill and injured patients getting advanced care in a timely manner, and this new service will help save lives."
With over 47 years of experience, Life Flight Network operates one of the most advanced and trusted air medical programs in the United States. Its expansion into the state of Hawai'i underscores its commitment to increasing access to lifesaving care in rural and underserved regions. The organization is currently hiring for their upcoming Hawai'i locations and qualified individuals are encouraged to apply. For those interested, please visit www.lifeflight.org/careers.
ABOUT LIFE FLIGHT NETWORK
Life Flight Network exists to fulfill its mission of saving lives through industry leading care and transport. It is the largest not-for-profit air medical service in the United States and is accredited by national and international accrediting bodies for safety, operations, and clinical excellence. Life Flight Network maintains its own FAA Part 135 Operating Certificate, offering ICU-level care during air and ground transport across the Pacific Northwest and Intermountain West. Headquartered in Aurora, Oregon, Life Flight Network is owned by a consortium of Legacy Health, Oregon Health and Science University, Providence Health and Services, and Saint Alphonsus Regional Medical Center. It was named the 2021 Program of the Year by the Association for Air Medical Services. For more information or to become a member visit www.lifeflight.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/life-flight-network-announces-timeline-for-expansion-into-hawaii-investing-27m-in-new-air-medical-operations-302480588.html
SOURCE Life Flight Network
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he experienced a heart attack on Father's Day in 2024 and what he's learned since then about high LDL or "bad" cholesterol—a leading, but often hidden risk factor for cardiovascular events.2-7 "I've spent my life as a professional athlete taking care of my body, but I had no idea I was living with a silent risk that could lead to a heart attack," said Sanders. "My message to other people is simple: don't wait. Get your LDL-C tested and talk to your doctor. Knowing your number is an important step to understanding your risk."7 More than 40% of adults with high LDL-C in the U.S. do not know their levels are high.8 The documentary educates viewers about LDL-C and how it can lead to a buildup of plaque in the arteries, putting individuals at risk of a cardiovascular event.5 "We know that high LDL-C is one of the leading, yet most modifiable, risk factors for heart attack and stroke.1 However, the cardiovascular disease public health crisis continues," said Paul Burton, M.D., senior vice president and chief medical officer at Amgen. "The Making of a Heart Attack should be a wake-up call for everyone. Amgen is committed to leading change by increasing LDL-C testing and encouraging patients and the entire healthcare system to act with urgency to overcome inertia and address this issue." Featured alongside Sanders sharing their own stories of living with cardiovascular disease are Hyvelle Ferguson-Davis, founder of Heart Sistas; Tara Robinson, CEO of the Black Heart Association; Gigi Campos, a WomenHeart Champion; and her father, Ponciano Gari. Sara Collins, M.D., FACC, an interventional cardiologist and member of the Association of Black Cardiologists, provides her expert medical perspective throughout. The documentary is part of Amgen's broader ambition to cut the number of heart attacks and strokes in the U.S. in half by 2030. Working with advocacy leaders, medical societies, healthcare systems and research institutions, Amgen is advancing efforts to drive earlier LDL-C testing, expand access to care and improve health outcomes. Watch The Making of a Heart Attack on June 14, 2025, at 1 p.m. ET on A&E (check local listings). The documentary will be available to watch online at beginning June 16, 2025 and will be featured at the Cannes Lions International Festival of Creativity 2025. To learn more about LDL-C, especially if you have cardiovascular disease, including how to get a free cholesterol test, visit Be sure to talk to your doctor about your results. About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads. Amgen Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed, and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media) Justin Claeys, 805-313-9775 (investors) REFERENCES Martin SS, et al. Circulation. 2024;149:e347-e913. Grundy SM, et al. J Am Coll Cardiol. 2019;73:3168-3209. McKinley EC, et al. Cardiovasc Drugs Ther. 2023;37:107-116. Wilkinson MJ, et al. J Am Heart Assoc. 2023;12:11:e028892:1-22. Understanding and Managing LDL (Bad) Cholesterol. American Heart Association. Accessed June 2025. Underberg J, et al. Postgrad Med. 2022;134:752-762. Heart Disease Risk Factors. Centers for Disease Control and Prevention. December 2, 2024. Accessed June 2025. Sayed A, et al. JAMA Cardiol. 2023;8(12):1185–1187. View original content: SOURCE Amgen Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture
PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform for healthcare, today announced the launch of two breakthrough AI agents—Skypoint Lia and Skypoint Scribe—designed to dramatically improve workflow efficiency, capturing social determinants of health data (SDOH), and clinical decision-making across care environments. Healthcare systems are increasingly overwhelmed by fragmented electronic health records (EHRs), redundant documentation, and mounting administrative demands. Skypoint's new agents address these challenges head-on, empowering clinicians to spend less time navigating systems and more time with patients. Skypoint Lia is a browser-based, EHR-agnostic AI agent that provides real-time, unified patient insights directly at the point of care. Working seamlessly across platforms like Epic, Cerner, MEDITECH, and PointClickCare, Lia overlays the EHR to surface demographics, payer information, care gaps, SDOH, and more—without any need for integration or disruption to existing systems. "Lia puts the full patient picture in front of clinicians in seconds," said Kishore Bhattacharjee, CTO at Skypoint. "It drives faster decisions, reduces missed opportunities, and improves documentation accuracy—all while ensuring enterprise-grade security." Skypoint Scribe complements Lia by tackling one of the biggest pain points in clinical settings: documentation and SDOH data capture. Scribe is a browser extension-based AI agent that captures and transcribes patient interviews in real time. From hospitals and skilled nursing facilities (SNFs) to home care and specialty clinics, Scribe eliminates duplicate entry by extracting key clinical details, such as medications, goals, and care directives, and auto-populating structured fields. Its AI capabilities streamline workflows, enhance compliance, and centralize data into a unified patient record stored securely in Skypoint's Data Lakehouse, using Data Lakebase for low-latency data management. "Clinical teams spend too much time duplicating data across systems," said Rob MacNaughton, President and COO of Skypoint. "Scribe transforms this experience by letting providers document while they care, not after the fact." Both Lia and Scribe are fully HIPAA-compliant, HITRUST r2-certified, and designed for rapid deployment, typically within minutes. Together, they represent a significant step forward in Skypoint's mission to reduce administrative burden and improve patient outcomes through intelligent automation. To learn more or request a demo, visit View original content to download multimedia: SOURCE Skypoint
Yahoo
3 hours ago
- Yahoo
Diagnostic Electrocardiograph/ECG Market worth US$15.18 billion by 2032 with 7.4% CAGR
DELRAY BEACH, Fla., June 13, 2025 /PRNewswire/ -- The global Diagnostic Electrocardiograph/ECG Market, valued at US$8.59 billion in 2024 stood at US$9.19 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2032, culminating in a forecasted valuation of US$15.18 billion by the end of the period. The growth in the ECG diagnostic market can be attributed to several critical factors. The rising prevalence of chronic conditions, particularly CVDs, is a significant driver. Additionally, there is a marked shift towards home healthcare solutions, propelled by advancements in wearable technology and the broader digital transformation within the healthcare sector. The burgeoning geriatric demographic, which is increasingly susceptible to cardiac disorders, further amplifies the demand for ECG diagnostics across various healthcare environments. Technological innovations, specifically the advent of portable ECG devices and AI-enhanced ECG interpretation, are enhancing diagnostic precision and improving patient accessibility. Moreover, government initiatives aimed at promoting cardiac health, coupled with a growing acceptance of point-of-care diagnostic methodologies, are anticipated to bolster market growth moving forward. Download PDF Brochure: Browse in-depth TOC on "Diagnostic Electrocardiograph/ECG Market" 150 - Tables60 - Figures250 - Pages By Product, the diagnostic ECG market is categorized into diagnostic ECG devices and diagnostic ECG software & services, with the diagnostic ECG devices segment commanding the largest market share. This predominance is attributable to the critical role these devices play in routine cardiac diagnostics, the swift identification of arrhythmias, and long-term cardiac monitoring. Standard resting ECGs serve as fundamental assessments in both primary care and specialized medical environments, while Holter monitors facilitate extensive and continuous cardiac surveillance over extended periods. The demand for these diagnostic tools is significantly influenced by the rising geriatric population, which correlates with an increase in CVD prevalence within this demographic. According to WHO, over 80% of CVD-related fatalities result from heart attacks and strokes, with one-third of these deaths occurring prematurely in individuals under 70 years of age; this statistic underscores the urgent need for effective cardiac monitoring solutions in the face of growing cardiovascular health challenges. By lead type, the diagnostic ECG market is categorized based on lead types into 12-lead, 5-lead, 3-lead, 6-lead, and single-lead ECG devices. Notably, 12-lead ECG systems dominate the market due to their superior diagnostic capabilities, allowing for precise measurement of cardiac electrical activity. Regarded as the gold standard for the advanced diagnosis of cardiac pathologies, including myocardial infarctions and arrhythmias, these systems are widely endorsed by clinical guidelines for use in hospitals and cardiology clinics. Their approval for emergency and critical care applications further cements their market leadership. Key manufacturers of 12-lead diagnostic ECG devices include Koninklijke Philips N.V. (Netherlands), ACS Diagnostics (US), OSI Systems, Inc. (US), and GE Healthcare (US). By type, the diagnostic ECG market is further segmented into portable, wearable, and implantable ECG devices. In 2024, the portable ECG devices segment accounted for the largest market share, driven by their convenience, mobility, and diverse applications in both clinical settings and home care. Unlike traditional ECG machines, which are typically bulkier and stationary, portable devices enable on-demand or continuous cardiac monitoring from virtually any location. A significant advantage of these devices is their ability to wirelessly record and transmit ECG data to healthcare providers, facilitating remote patient monitoring. This capability not only allows for timely interventions but also minimizes the need for frequent hospital visits, which is particularly beneficial for patients with chronic heart conditions. As a result, the emphasis on remote patient care and the demand for personalized healthcare solutions are the primary factors propelling the growth of portable ECG devices, solidifying their dominant position within the diagnostic ECG market. By end user, the diagnostic ECG market is segmented into hospitals, primary care centers, cardiac centers, ambulatory surgery centers, urgent care settings, and home care settings. The hospitals segment held the largest market share primarily due to the high volume of cardiovascular patient admissions and the presence of state-of-the-art diagnostic infrastructure. The integration of ECG systems with other cardiac diagnostic modalities enhances their utility in both inpatient and outpatient settings, especially within emergency and ICUs. The increasing rates of hospital admissions for cardiac conditions, combined with the emphasis on early detection and timely intervention, position hospitals as the predominant end users of ECG technologies; this trend is a key driver of overall market expansion in the diagnostic ECG market. By geography, the diagnostic ECG market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The North American market has successfully secured a substantial share, driven by several key factors. One major contributor is the growth in the geriatric population, which is leading to an increased demand for healthcare services and diagnostic tools. Alongside this demographic shift, there has been a notable rise in the prevalence of chronic diseases, such as CVDs and diabetes, that require regular monitoring and management through advanced diagnostic ECG solutions. Additionally, the enhancement of healthcare infrastructure in the region plays a crucial role in facilitating better access to these diagnostic services. Hospitals & clinics are increasingly equipped with state-of-the-art technology and resources, enabling healthcare providers to offer timely and effective care. Furthermore, supportive government initiatives aimed at improving healthcare accessibility also have a positive impact on the market. Policies designed to reduce barriers to healthcare services and promote innovative diagnostic technologies are helping to ensure that patients can receive necessary care without significant obstacles. The strategic expansion of key players in the North American market, which includes both established companies and emerging startups, is anticipated to further bolster market growth. The active presence of these industry leaders not only enhances competition but also drives innovation in product development, ultimately benefiting patients and healthcare providers alike. Overall, these factors collectively signify a robust growth trajectory for the ECG diagnostic solutions market in North America. Request Sample Pages : As of 2024, diagnostic ECG market was dominated by GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Baxter (US), FUKUDA DENSHI (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), NIHON KOHDEN CORPORATION (Japan), OSI Systems, Inc. (US), Bittium (Finland), iRhythm Technologies, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Midmark Corporation (US), BPL Medical Technologies (India), SCHILLER (Switzerland), ACS Diagnostics (US), Allengers (India), and Bionet Co., Ltd. (South Korea), among others. GE Healthcare (US): GE Healthcare is a well-established entity in the diagnostic ECG sector, boasting over 125 years of industry experience and a formidable reputation within the global healthcare landscape. The company effectively utilizes its extensive global footprint in medical technology, diagnostics, and digital solutions, catering to a diverse clientele across 160 countries while adhering to sustainable operational practices. Central to GE Healthcare's strategy is a robust emphasis on R&D to optimize existing offerings and innovate new products and services. This commitment allows the company to stay responsive to evolving customer demands and to capitalize on emerging market opportunities. In a notable move for 2024, GE Healthcare invested approximately USD 969 million to enhance manufacturing capabilities and local R&D initiatives in India over the next five years. The company's growth strategy encompasses a range of collaborations, agreements, expansions, and acquisitions to strengthen its operational reach and market presence. These strategic endeavors not only expand the product portfolio but also fortify the company's competitive standing in the market. In a recent development, GE Healthcare partnered with the Mayo Clinic in September 2023 to leverage advanced technologies and improve the precision of diagnostics and treatment processes for healthcare providers. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. (Royal Philips) serves as the parent organization of the Philips Group, strategically operating across four core domains: Personal Health, Diagnosis & Treatment, Connected Care, and Others. Within the Connected Care segment, Philips provides advanced diagnostic solutions, including cardiographs, Holter monitoring systems, and stress-testing ECGs. The company's growth strategy is heavily centered on forming strategic partnerships in high-potential markets and fostering collaborative efforts to drive innovation. A notable example of this approach is the 2023 partnership with NYU Langone Health to leverage innovative technologies and enhance patient care over an eight-year span. Additionally, in January 2025, Philips is set to present its latest innovations at Arab Health 2025. These advancements emphasize the integration of smart systems, automation, and cloud-based informatics into healthcare delivery, targeting reductions in clinician workload and improvements in operational workflows, ultimately leading to enhanced patient outcomes. Key subsidiaries within the Philips ecosystem include Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). The company maintains a comprehensive operational footprint across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Shenzhen Mindray Bio-Medical Electronics Co. (China) Shenzhen Mindray Bio-Medical Electronics is a prominent entity in the diagnostic ECG segment, distinguished by its diverse operational structure across three primary business verticals: Patient Monitoring and Life Support, In-vitro Diagnostics, and Medical Imaging Systems. Within the Patient Monitoring & Life Support sector, the company delineates its offerings into Patient Monitoring Systems, ECG devices, and ancillary products. Mindray dedicates more than 10% of its revenue to R&D, which underpins its commitment to innovation and sustains a formidable portfolio of over 3,000 patents. This investment not only fuels technological advancement but also strengthens its competitive edge. The company has also established strategic partnerships to enhance its market penetration and product offerings. Notably, its collaboration with Amazon Business facilitates improved access to medical equipment for healthcare systems, hospitals, and practitioners, streamlining procurement and distribution channels in a rapidly evolving healthcare landscape. For more information, Inquire Now! Related Reports: Cardiac Monitoring & Cardiac Rhythm Management Devices Market Patient Monitoring Devices Market Brain Monitoring Market Patient Temperature Monitoring Market MRI Systems Market Get access to the latest updates on Diagnostic Electrocardiograph/ECG Companies and Diagnostic Electrocardiograph/ECG Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets
